Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Pergolide helps manage equine PPID, study finds
The pergolide treatment did not have any effect on horses which were diagnosed with ID only.
The drug reduced blood insulin levels in horses with both PPID and ID.

A new study has highlighted the benefits of using pergolide mesylate to treat horses diagnosed with pituitary pars intermedia dysfunction (PPID).

The drug, which is already commonly used for treating the condition, proved to be effective in reducing the amount of insulin produced by horses when eating.

PPID, also known as Cushing's syndrome, affects the pituitary gland at the base of a horse's brain which produces hormones in response to brain signals. When damaged due to PPID, there can be excessive production of normal hormones, leading to issues such as laminitis and weight loss.

The risk of developing laminitis is higher in horses also diagnosed with insulin dysregulation (ID). A high concentration of insulin is now recognised as the leading cause of laminitis in the UK.

A research project, published by the University of Melbourne, sought to investigate how effective pergolide was at managing the clinical signs of PPID.

The study saw 16 senior horses (eight with PPID and ID, eight with ID only) take part in a standard meal test. Researchers measured the horses' insulin concentration before and after they had eaten a high starch meal.

All of the horses did the standard meal test twice, once after four weeks of pergolide treatment and once without pergolide treatment.

The results revealed that pergolide was an effective treatment for horses with both PPID and ID. Horses treated with pergolide recorded blood insulin levels at the same level as horses that only had ID.

However, the pergolide treatment did not have any effect on horses which were diagnosed with ID only. Researchers say that this highlights the importance of testing for PPID and ID separately, as treating one may not manage the other.

The study also found that, even when treated with pergolide, the horses diagnosed with PPID or ID still produced more insulin from starchy, sugary meals than healthy horses. Researchers say that a low sugar and starch diet remains vital for managing horses with PPID and ID.

The full study has been published in the Equine Veterinary Journal.

Image © Shutterstock

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.